Error loading player: No playable sources found
Business Continuity During and After the Pandemic: What Lessons Can Be Taken to the Future? - SPANISH
Date
August 12, 2021
This product is not available for individual purchase, but it is available as part of the following products:
Speaker
Session Chairs
Bayer S.A. – Brazil
Seagen Inc.
AbbVie, Inc.
Genentech, a Member of the Roche Group
Session Speakers
ANVISA-National Health Surveillance Agency
Amgen (Europe) GMBH, Switzerland
Pfizer Limited, United Kingdom - representing FIFARMA
Panel Members
ANMAT- National Administration of Medicines, Food and Medical Technology
COFEPRIS-Federal Commission for the Protections from Sanitary Risks
DIGEMID-General Directorate of Medicines, Supplies and Drugs
Related Products
New Trends in Comparability
Comparability is a well-established scientific concept that is pivotal to biological product realisation. It successfully enables product development and lifecycle management of existing products and the development of biosimilars…
CMC ASAP: Accelerated and Streamlined CMC Development for Emerging and Rare Diseases
CMC development is often rate limiting for initiation of first in human studies, continuation to late stage development, and ultimately commercialization. The challenge is particularly acute for emerging and rare disease indications…
Business Continuity During and After the Pandemic: What Lessons Can Be Taken to the Future? - ENGLISH
The ongoing COVID-19 pandemic poses challenges to all National Regulatory Authorities (NRAs) and industry in the short, medium and long term…
